# RxSight, Inc. (RXST) · Edgar & Edgarette company card

> RxSight (RXST) saw revenue fall 3.9% in FY2025 to $134 million, operating margin -35.8% against a 5.9% median for ophthalmic goods, equity 88.4% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1111485 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/RXST) · [JSON](https://www.pops4.com/boards/company/RXST.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $134M |
| Revenue growth, 1 year | -3.9% |
| Revenue growth per year | 56.2% |
| Operating margin | -35.8% (prior year -26.3%) |
| Net margin | -29.0% |
| Operating cash flow | −$16M |
| Capital spending | $4M |
| Free cash flow | −$19M |
| Cash | $20M |
| Long-term debt | — |
| Total assets | $312M |
| Total equity | $276M |
| Equity ÷ assets | 88.4% |
| Return on equity | -14.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 5.56 (safe zone)
- Piotroski F: 3 of 9 (middling)
- Beneish M: -3.13 (below the −1.78 line)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative; operating loss: a margin of -35.8% in FY2025; revenue is hard to predict: its 80% range is ±40%
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $134.5M (FY2025). Experience: revenue down 3.9% on the year, up 56.2% a year over 4 years; operating margin -35.8%, down from -26.3%. Soundness: equity 88.4% of assets, return on equity -14.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $102.6M and $238.6M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $82.9M to $297.9M. A statistical range, not company guidance. Against peers (147 filers, $50M+ revenue, its industry group): operating margin -35.8% against a 5.9% median; growth -3.9% against 7.9%.

Range logged 2026-10-31, receipt ae4e6b1174d88fb0, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 5, latest 2026-07-15 ([filing](https://www.sec.gov/Archives/edgar/data/1111485/000119312526304812/0001193125-26-304812-index.htm))

## Recent filings

- 10-Q · filed 2026-11-03 · [filing](https://www.sec.gov/Archives/edgar/data/1111485/000119312526445381/0001193125-26-445381-index.htm)
- 8-K · filed 2026-11-03 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1111485/000119312526445318/0001193125-26-445318-index.htm)
- 10-Q · filed 2026-08-05 · [filing](https://www.sec.gov/Archives/edgar/data/1111485/000119312526335153/0001193125-26-335153-index.htm)
- 8-K · filed 2026-08-05 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1111485/000119312526335150/0001193125-26-335150-index.htm)
- 8-K · filed 2026-07-15 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1111485/000119312526304812/0001193125-26-304812-index.htm)
- 8-K · filed 2026-07-06 · 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1111485/000119312526296201/0001193125-26-296201-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001111485.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1111485

## Cite

POPS4, Edgar & Edgarette: RxSight, Inc. (RXST) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/RXST. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.